Paralyzed 8-year-old walks again after new treatment revives cell energy system
An eight-year-old boy’s sudden loss of mobility became the first real-world test of a biochemical discovery that may shape future treatments for rare mitochondrial diseases.
Diagnosed with a fatal condition called HPDL deficiency, the boy was confined to a wheelchair within just three months.
The disorder disrupts the production of CoQ10, a coenzyme essential for converting sugars and fats into energy inside mitochondria, the cell’s powerhouses, leading to paralysis, limb stiffness, and severe fatigue.
Now, researchers at NYU Langone Health report that an experimental compound targeting CoQ10 production helped reverse his paralysis.
Paralyzed child walks again
Within two months of starting treatment, the boy was able to walk long distances again, marking a potential breakthrough in treating mitochondrial disorders.
The treatment stemmed from a 2021 discovery by Dr. Michael Pacold’s lab at NYU Langone, which revealed how cells begin producing CoQ10. The team identified that an enzyme called HPDL converts a molecule called 4-HMA into 4-HB, a critical step in CoQ10 synthesis.
Building on this insight, the researchers showed in mouse models that supplementing with 4-HMA or 4-HB restored CoQ10 production, countering paralysis and extending survival.
Interestingly, the discovery of 4-HB’s potential came while the team was investigating cancer metabolism. The effects on neurodegeneration emerged unexpectedly, highlighting how breakthroughs sometimes arise from unrelated lines of inquiry.
Inspired by these results, the team sought emergency approval to use 4-HB under the FDA’s expanded access program, a pathway allowing experimental treatments for patients with no alternatives.
Once authorized, the boy began receiving daily doses of 4-HB dissolved in water. Within weeks, his balance and endurance improved noticeably. Two months into treatment, he was able to walk over a mile with his family, offering rare hope in a condition that is typically irreversible.
Unlocking cell energy pathways
While the recovery was not complete, some stiffness and gait challenges remained. Researchers said the outcome marks the first known case of reversing neurological symptoms in HPDL deficiency by supplying CoQ10 precursors rather than CoQ10 itself.
“To our knowledge, this is the first demonstration that neurological symptoms of a primary CoQ10 deficiency can be stabilized or improved by supplying not CoQ10 itself, but instead its smaller, more easily processed precursors, which cells then use to build more of the coenzyme,” said Dr. Pacold, senior author of the new study.
The NYU Langone team now plans to investigate the treatment’s timing and dosage more deeply, aiming to identify a critical window in neural development when CoQ10 precursor therapy may be most effective.
The team’s mouse studies suggest there is a critical period in brain development when the effects of HPDL deficiency can still be reversed using CoQ10 precursors. After this window closes, treatment may have little impact, making early diagnosis and intervention key to future patient outcomes.
Beyond rare genetic conditions like HPDL deficiency, CoQ10 levels are known to decline with aging, heart disease, diabetes, and neurodegenerative disorders such as Alzheimer’s.
The researchers believe precursor-based treatments like 4-HB could eventually offer a more effective alternative to standard CoQ10 supplements, which are poorly absorbed by the body.
Source: Interesting Engineering
Surprise Hair Loss Breakthrough: DNA Sugar Gel Triggers Robust Regrowth
Paralyzed 8-year-old walks again after new treatment revives cell energy system